📱 Now on iPhone — live scores, valuations & alerts on the go
3 free score cards remaining
Transcode Therapeutics, Inc. (RNAZ)
Healthcare
Inconclusive
weak
$2.06
Updated: 2026-08-31
41
TradeApes Score
Financial Strength
10
Stressed
Operating Trend
30
Weak
Relative Value
60
Fair value
Capital Allocation
50
Mixed
Risk Management
80
Strong
Key Findings
+
Historically cheap — EV/EBITDA in bottom 25% of its 5-year range
−
Very high leverage — net debt/EBITDA above 5×
Industry Related Stocks
Get RNAZ and 3,000+ stocks in your pocket
Health scores, fair-value estimates, and full company analysis — free on iPhone.
Download iPhone App
TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor.
The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.
Sign up for our Weekly Sector Leaders Newsletter
11 sector-leading stocks delivered to your inbox every Sunday. Free.
No spam. Unsubscribe anytime.